These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 21801213)

  • 21. Introduction to "A road map for intravenous iron and anemia management: preparing for the future".
    Coyne DW
    Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S1-4. PubMed ID: 19010256
    [No Abstract]   [Full Text] [Related]  

  • 22. Novel erythropoiesis-stimulating agents: a new era in anemia management.
    Macdougall IC
    Clin J Am Soc Nephrol; 2008 Jan; 3(1):200-7. PubMed ID: 18077782
    [TBL] [Abstract][Full Text] [Related]  

  • 23. EPO adjuvant treatments: a need for more evidence.
    Fishbane S
    Am J Kidney Dis; 2006 Apr; 47(4):683-5. PubMed ID: 16564947
    [No Abstract]   [Full Text] [Related]  

  • 24. Current and future challenges in anaemia management.
    Levin A; Locatelli F; Muirhead N; Ritz E
    Nephrol Dial Transplant; 2005 Jun; 20 Suppl 6():vi1-2. PubMed ID: 15958819
    [No Abstract]   [Full Text] [Related]  

  • 25. Quality of life in CKD patients treated with erythropoiesis-stimulating agents.
    Parfrey PS; Wish T
    Am J Kidney Dis; 2010 Mar; 55(3):423-5. PubMed ID: 20189050
    [No Abstract]   [Full Text] [Related]  

  • 26. The controversy surrounding hemoglobin and erythropoiesis-stimulating agents: what should we do now?
    Singh AK
    Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S5-13. PubMed ID: 19010260
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Finding the magic formula for ESA use.
    Neumann ME
    Nephrol News Issues; 2010 May; 24(6):8. PubMed ID: 20509399
    [No Abstract]   [Full Text] [Related]  

  • 28. To treat or not to treat renal anemia of chronic kidney disease patients?
    Tsubakihara Y
    Ther Apher Dial; 2010 Jun; 14(3):235-9. PubMed ID: 20609177
    [No Abstract]   [Full Text] [Related]  

  • 29. FDA approval of Omontys changes the ESA playing field.
    Neumann ME
    Nephrol News Issues; 2012 May; 26(6):17. PubMed ID: 22690453
    [No Abstract]   [Full Text] [Related]  

  • 30. Triumph and tragedy: anemia management in chronic kidney disease.
    Novak JE; Szczech LA
    Curr Opin Nephrol Hypertens; 2008 Nov; 17(6):580-8. PubMed ID: 18941350
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evolving regulatory landscape with erythropoiesis-stimulating agents and impact on managed care.
    Fatodu H
    Am J Manag Care; 2010 Mar; 16 Suppl Issues():S74-9. PubMed ID: 20297875
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anaemia of CKD--the CHOIR study revisited.
    Singh AK; Szczech L; Tang KL; Barnhart H; Sapp S; Wolfson M; Reddan D
    Nephrol Dial Transplant; 2007 Jul; 22(7):1806-10. PubMed ID: 17420166
    [No Abstract]   [Full Text] [Related]  

  • 33. Revised European Best Practice Guidelines for the management of anaemia in patients with chronic renal failure, part III.2: treatment of anaemia with iron.
    Vaage-Nilsen O
    Nephrol Dial Transplant; 2005 Jul; 20(7):1512-3; author reply 1513-4. PubMed ID: 15967789
    [No Abstract]   [Full Text] [Related]  

  • 34. Costs of managing anemia with erythropoiesis-stimulating agents during hemodialysis: a time and motion study.
    Schiller B; Doss S; DE Cock E; Del Aguila MA; Nissenson AR
    Hemodial Int; 2008 Oct; 12(4):441-9. PubMed ID: 19090867
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anemia and response to epoetin alfa: the cause of anemia matters!
    Dharmarajan TS
    J Am Geriatr Soc; 2008 Aug; 56(8):1574-5. PubMed ID: 18808607
    [No Abstract]   [Full Text] [Related]  

  • 36. Finding a rational approach to ESA therapy--for payers and patients.
    Messana A
    Nephrol News Issues; 2007 Sep; 21(10):54, 56. PubMed ID: 17918481
    [No Abstract]   [Full Text] [Related]  

  • 37. Myocardial bridge in a patient with sickle cell anemia.
    de Seixas MA; Franchin Júnior CA; Silva CE; Leal SM; Ortiz J
    Arq Bras Cardiol; 1999 Feb; 72(2):191-200. PubMed ID: 10488578
    [No Abstract]   [Full Text] [Related]  

  • 38. Relative mortality and epoetin alpha dose among hemodialysis patients.
    Coyne DW
    Am J Kidney Dis; 2008 May; 51(5):866-7; author reply 867. PubMed ID: 18436101
    [No Abstract]   [Full Text] [Related]  

  • 39. Relative mortality and epoetin alpha dose in hemodialysis patients.
    Cotter DJ; Thamer M; Zhang Y
    Am J Kidney Dis; 2008 May; 51(5):865; author reply 865-6. PubMed ID: 18436099
    [No Abstract]   [Full Text] [Related]  

  • 40. Quality of life and anemia: the nephrology experience.
    Macdougall IC
    Semin Oncol; 1998 Jun; 25(3 Suppl 7):39-42. PubMed ID: 9671329
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.